The rising number of surgeries worldwide is driving the adhesion barrier market. Postsurgical adhesions are common after abdominal, gynecological, and orthopedic operations. Adhesion barrier products are being used more to avoid surgical adhesions due to increased demand.
Technological advances affect the adhesion barrier industry. Adhesion barriers are being improved using new materials and formulas. The market is evolving due to bioresorbable and synthetic adhesion barriers with increased biocompatibility and lower adverse effects.
Adhesion-related issues such as intestinal blockages and infertility drive market expansion. Adhesions following operations might cause issues that need extra medical treatment. Postoperative adhesions and problems may be prevented using adhesion barriers.
Adhesion barrier sales are rising as patients demand less invasive procedures. To reduce tissue stress, patients and doctors are choosing smaller incisions. In minimally invasive operations, adhesion barriers prevent adhesions without sacrificing results.
Adhesion barriers are in high demand for gynecological surgery, especially fertility and pelvic surgeries. Infertility and pelvic discomfort drive the demand for effective adhesion prevention methods to improve surgical results and patient quality of life.
The rise in orthopedic and abdominal procedures affects the adhesion barrier industry. These operations commonly manipulate tissues, which might cause adhesions. Postoperative problems including tissue stickiness and limited mobility are reduced by adhesion barriers.
Market drivers include regulatory backing and adhesion barrier standards. Regulatory organizations are realizing the importance of surgical adhesion avoidance and offering clear recommendations for product development and use. Adhesion barrier solutions are safe and effective when regulated.
Adhesion barriers are being replaced by cheaper alternatives. New materials and formulas that inhibit adhesion at reduced costs are being developed by manufacturers, making these solutions more affordable for patients and healthcare institutions.
Continuing research and development are improving adhesion barrier technology. Company investments are on next-generation products with greater biocompatibility, durability, and impact longevity. These investments meet surgeons' and patients' changing demands in many surgical specialties.
Global utilization of adhesion barriers is rising in developed and emerging nations. Emerging markets are driving market expansion as awareness of adhesion avoidance in various surgical procedures rises.
Adhesion Barrier Market Size was valued at USD 0.643 billion in 2023. The adhesion barrier market industry is projected to grow from USD 0.6894 billion in 2024 to USD 1.123 billion by 2032, exhibiting a compound annual growth rate (CAGR) of 6.29% during the forecast period (2024 - 2032).One of the main market driver propelling the expansion of the market for adhesion barriers is the rise in the number of invasive procedures with a high risk of postoperative problems.
Source: Secondary Research, Primary Research, MRFR Database and Analyst Review
Increased obese population is driving the market growth
The increase in post-operative adhesion incidence is predicted to affect the market for adhesion barriers substantially. Risk of abdominal adhesion exists for 90% of individuals undergoing abdominal surgery, particularly laparotomies. Abdominal adhesion barriers form in only 10% of patients. Laparotomies are routinely performed in response to difficult appendicectomies, small intestine problems, gastrointestinal cancer, hysterectomy, and ectopic pregnancy. In the US, about 9 million procedures are performed on the abdomen and pelvis each year. Around 94% of C-sections result in adhesions, however with adhesiolysis and gastrointestinal surgery, that rate drops to between 65% and 75%. Non-surgical adhesions include, among other things, diverticular illnesses, abdominal TB, and inflammatory bowel disease. Endometriosis and pelvic inflammatory diseases are the two conditions that produce adhesion the most frequently.
In recent years, surgeons all over the world have increasingly used adhesion barrier agents. Women experience adhesions following gynecological postpartum treatments, which can result in various gynecological issues like infertility, persistent discomfort, and inflammation. During surgical procedures, this affects the adhesion barrier films that surgeons choose. Because of the problems caused by post-surgical adhesion, both total morbidity and treatment costs have increased. Sticky small intestinal blockage in North America has been associated with more than 300,000 hospital admissions, 850,000 days spent in hospitals, and a cost of roughly US$ 1.3 billion.
Due to urbanization and rising disposable incomes, sedentary lifestyles are being adopted by an increasing number of people globally. As a result, a variety of lifestyle issues, such as obesity, cancer, hypertension, and others, are becoming more prevalent. 39% of adults globally are overweight, and 9.8% of individuals have diabetes. Diabetes, according to the World Health Organisation (WHO), significantly increases the risk of renal failure, strokes, lower limb amputations, heart attacks, blindness, and heart attacks. In addition, 26% of people have hypertension, and by 2030 that number is projected to reach 29%. Due to these conditions, it is more common for young people to develop diseases like cancer, stroke, and heart failure, which is increasing the demand for adhesion barriers. Thus, driving the adhesion barrier market revenue.
The adhesion barrier market segmentation, based on product includes Synthetic Adhesion Barriers, Natural Adhesion Barriers, Formulation and Severity. The synthetic adhesion barriers category dominated the market because they are biocompatible and bioresorbable. Cost-effectiveness of synthetic adhesion barriers is anticipated to drive uptake of the product category. Furthermore, commercial synthetic adhesion barriers are widely available, largely responsible for the segment's domination.
Figure 1: Adhesion Barrier Market, by Product, 2023 & 2032 (USD billion)
Source: Secondary Research, Primary Research, MRFR Database and Analyst Review
The adhesion barrier market segmentation, based on application, includes Gynecological Surgeries, General/Abdominal Surgeries, Orthopedic Surgeries, Cardiovascular Surgeries, Neurological Surgeries, Urological Surgeries, and Reconstructive Surgeries. The cardiovascular surgeries category generated the most income. The primary factors driving growth in this region of the advanced adhesion barrier market are the rising prevalence of heart-related disorders and the expanding use of adhesion barriers during cardiovascular surgery.
By Region, the study provides the market insights into North America, Europe, Asia-Pacific and Rest of the World. The North American adhesion barrier market area will dominate this market. The rising incidence of sports-related injuries and the need for adhesion barriers in treatment methods are the main drivers fueling the market's expansion in terms of revenue in this area. Furthermore, the region's countries are seeing a growth in the number of innovations by significant market players as a result of their strong presence there.
Further, the major countries studied in the market report are The U.S., Canada, German, France, the UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.
Figure 2: ADHESION BARRIER MARKET SHARE BY REGION 2023 (%)
Source: Secondary Research, Primary Research, MRFR Database and Analyst Review
Europe adhesion barrier market accounts for the second-largest market share due to its sizable senior population, which necessitates medical care for orthopedic disorders and growing operations, hence fueling growth during the predicted period. The people are becoming more aware of the advantages of adhesion barriers, more laparoscopies and gynecology operations are being performed, and hospital readmission rates are rising. Further, the German adhesion barrier market held the largest market share, and the UK adhesion barrier market was the fastest growing market in the European region
The Asia-Pacific Adhesion barrier Market is expected to grow at the fastest CAGR from 2023 to 2032. The region's rapid rise is primarily explained by the region's growing senior population and rising rates of cardiac and neurosurgery, all of which necessitate surgical procedures. Additionally, increased medical tourism and rising private sector investment in healthcare are anticipated to fuel the region's adhesion barrier market's expansion. Moreover, China’s adhesion barrier market held the largest market share, and the Indian adhesion barrier market was the fastest growing market in the Asia-Pacific region.
Adhesion Barrier Key Market Players & Competitive Insights
Leading market players are investing heavily in research and development in order to expand their product lines, which will help the adhesion barrier market, grow even more. Market participants are also undertaking a variety of strategic activities to expand their footprint, with important market developments including new product launches, contractual agreements, mergers and acquisitions, higher investments, and collaboration with other organizations. To expand and survive in a more competitive and rising market climate, adhesion barrier industry must offer cost-effective items.
Manufacturing locally to minimize operational costs is one of the key business tactics used by manufacturers in the adhesion barrier industry to benefit clients and increase the market sector. In recent years, the adhesion barrier industry has offered some of the most significant advantages to medicine. Major players in the adhesion barrier market attempting to increase market demand by investing in research and development operations include Profiled, Johnson & Johnson, Anika Therapeutics, Atrium Medical Corporation (A Part of Getinge Group), Baxter International, Betatech Medical, C. R. Bard, FzioMed, Innocoll Holdings, Integra LifeSciences Holdings Corporation, MAST Biosurgery, Normedi Nordic and Sanofi.
The company Baxter International Inc. (Baxter) offers a variety of medical supplies. Dialysis for both acute and chronic illnesses, sterile intravenous solutions, generic injectable medications, parenteral nutrition therapies, infusion systems and devices, inhaled anaesthetics, and surgical hemostat and sealant products are among the company's product and service offerings. Hospitals, rehabilitation facilities, kidney dialysis clinics, nursing homes, and patients' homes all use the company's products. In February 2020, for $350 million, Baxter International completed the purchase of Seprafilm Adhesion Barrier and related assets from Sanofi. In several pelvic and abdominal procedures, the Seprafilm product family is used as an adjuvant to lessen adhesions' frequency, severity, and length.
Anika Therapeutics Inc. (Anika) creates, produces, and distributes therapeutic treatments for traumatic situations and degenerative orthopedic illnesses. It offers veterinary, orthobiologic, cutaneous, ophthalmic, and surgical remedies. Visco-supplementation for humans and animals, joint implants, instrumentation devices, joint replacement goods, regenerative and orthopedic surgery therapies, bone repair therapy, advanced wound care, and ophthalmic products are some of its main product categories. In January 2020, Anika Therapeutics recently announced that it had signed contracts to buy Parcus Medical, a well-known sports medicine supplier, and Arthrosurface, a leading producer of joint surface and preservation solutions for active patients. The purchases are expected to accelerate Anika's growth by broadening its product range to encompass joint preservation and restoration.
Key Companies in the adhesion barrier market include
Profiled
Anika Therapeutics
Atrium Medical Corporation (A Part of Getinge Group)
Baxter International
Betatech Medical
C. R. Bard
FzioMed
Innocoll Holdings
Integra LifeSciences Holdings Corporation
MAST Biosurgery
Normedi Nordic
Sanofi
Adhesion Barrier Industry Developments
June 2022:The bio-regenerative medicine business CGBIO entered the Indonesian market with MEDICLORE, a fourth-generation sol-gel type anti-adhesion agent. When MEDICLORE is administered to the body, it changes from a sol state at ambient temperature to an extremely viscous gel state at body temperature. In order to prevent adhesion as the wound heals, this gel-like state serves as a physical barrier in the surgical site.
February 2022:In a statement from Gunze Limited, the company said that TENALEAF, the first sheet-type absorbable adhesion barrier made in Japan, has received medical device approval. The company plans to launch the gadget in the Japan market in March 2022 through its affiliate, Gunze Medical Japan. Gunze developed its absorbable adhesion barrier using cutting-edge absorbable material technology in an effort to provide a ground-breaking solution in this industry.
Synthetic Adhesion Barriers
Natural Adhesion Barriers
Formulation
Severity
Gynecological Surgeries
General/Abdominal Surgeries
Orthopedic Surgeries
Cardiovascular Surgeries
Neurological Surgeries
Urological Surgeries
Reconstructive Surgeries
Adhesion Barrier Regional Outlook
© 2024 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)